{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-078781","form_type":"8-K","ticker":"JSPR","cik":"0001788028","company_name":"Jasper Therapeutics, Inc.","filed_at":"2026-07-16T21:15:34+00:00","discovered_at":"2026-07-16T21:16:00.295994+00:00","generated_at":"2026-07-16T21:16:04.059284+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Jasper Therapeutics completes all-stock acquisition of Kira Pharmaceuticals and $132M PIPE","bullets":["Jasper acquires Kira in all-stock deal; pre-deal Jasper holders own ~6.68%, Kira holders ~49.86%, PIPE investors ~43.46% of combined company.","Concurrent $132M private placement co-led by Affinity Asset Advisors and Ikarian Capital; expected to close July 20, 2026.","Kira out-licenses KP-301 and KP-402 to Mirador Therapeutics for $12M upfront plus potential milestones.","Combined company cash runway through H2 2028; key milestones include KP-104 Phase 2 renal data in Q4 2026 and end-of-Phase 2 FDA meeting for PNH in H1 2027.","Briquilimab pre-BLA meeting for SCID expected in Q1 2027; KP-701 IND/CTA filing in Q1 2027 with first-in-human data in Q3 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-078781","json":"https://secwatch.observer/filing/0001213900-26-078781.json","markdown":"https://secwatch.observer/filing/0001213900-26-078781.md","text":"https://secwatch.observer/filing/0001213900-26-078781.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1788028/000121390026078781/0001213900-26-078781-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1788028/000121390026078781/ea0298316-8k_jasper.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-16T21:16:04.059284+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}